UNC-GO Program Faculty
Primary Preceptors serve as primary advisors, co-advisors, and consultants in one or more areas of expertise. They attend the annual Geriatric Oncology Research Symposium, and many serve as presenters for the UNC-GO monthly seminars.
UNC faculty with expertise in UNC-GO areas of emphasis are eligible to become UNC-GO preceptors at any time during the year. To include faculty from all relevant disciplines, the UNC-GO’s Co-Directors and Steering Committee may identify and invite potential preceptors to participate, using the following criteria:
- Commitment to, and experience in, multidisciplinary and collaborative cancer care quality applied research, as exemplified by publications and/or grant funding;
- Ongoing relevant funded research and access to studies and data that could assist and promote trainee training and career development;
- Sufficient position/seniority in their respective fields to act as preceptors;
- Track record of successful mentoring of postdoctoral trainees.
The UNC-GO will begin with nine primary faculty preceptors, representing several cancer disciplines (see below). All primary preceptors are UNC faculty with strong mentorship records, robust research programs, and substantial external funding. All have medical degrees. Most of the primary preceptors have primarily mentored MDs/DOs, but some have also mentored non-clinician postdoctoral trainees. UNC-GO faculty have a diverse, robust funding portfolio that supports trainee activities with average annual funding per preceptor >$1 million direct in the current year. All hold research, quality care and other leadership roles within UNC-LCCC and the UNC SOM that are pertinent to UNC-GO. Considered as a group, the nine primary preceptors provide myriad multidisciplinary research training opportunities.
|Primary Preceptors||Department(s)||Area of interest|
|Hyman Muss, MD|
|Jan Busby-Whitehead, MD|
|Ethan Basch, MD MSc||Professor of Medicine, Hematology/ Oncology; UNC-LCCC Director of Cancer Outcomes Research Program||Dr. Basch is a medical oncologist and health services researcher. His clinical expertise is prostate cancer, and his research expertise includes patient-reported symptoms outcomes during cancer treatment, drug regulatory policy, and comparative effectiveness research. He is a member of the Board of Scientific Advisors of the NCI, a federally appointed member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), Co-Chair of the Cancer Care Delivery Research Committee of the Alliance for Clinical Trials in Oncology, and Associate Editor of the Journal of the American Medical Association (JAMA).|
|Chad Pecot, MD||Assistant Professor of Medicine, Hematology/ Oncology; UNC-LCCC||Dr. Pecot is a lung cancer specialist with a particular interest in how RNA interference (RNAi) can regulate cancer metastases. He is studying how nanoparticle-based platforms can be exploited to target the metastatic process. Dr. Pecot recently received a $2 million R01 grant to support his research into the treatment of squamous cell lung cancer metastasis.|
|Victoria L. Bae-Jump, MD PhD||Associate Professor, Obstetrics and Gynecology; UNC-LCCC||Dr. Bae-Jump specializes in Gynecologic Oncology and procedures and research in surgery and chemotherapy for gynecologic malignancies; translational research in ovarian and endometrial cancer; and novel therapeutics for endometrial cancer. Her research focuses on understanding interactions between cell signaling pathways implicated in endometrial cancer pathogenesis as a means to target therapy for this disease. Her support includes a $800,000 American Cancer Society Research Scholar grant, “Obesity, Cation-Selective Transporters and Metformin in Endometrial Cancer” and an R01 grant, “Liposomal doxorubicin and pluronic combination for cancer therapy”.|
|Ron Chen, MD MPH||Radiation Oncology;
Associate Director of Education, UNC-LCCC
|Dr. Chen is Associate Professor, Radiation Oncology; Director, Radiation Oncology Residency Program; and Associate Chair for Education. As UNC-LCCC Associate Director of Education, his responsibilities include supporting and finding synergistic opportunities across oncology-related educational/training programs. His clinical expertise is in genitourinary cancers and Cyber knife radiation, and his research expertise includes long-term outcomes of prostate cancer patients and survivors. He was recently awarded a $11.9 million grant from the Patient-Centered Outcomes Research Institute (PCORI) to study outcomes in patients receiving different types of radiation treatments for prostate cancer.|
|Lisa A. Carey, MD||Chief, Division of Hematology & Oncology|
|William Y. Kim, MD||Rush S. Dickson Distinguished Associate Professor of Medicine, Hematology/ Oncology; Associate Professor of Genetics; UNC-LCCC||Dr. Kim’s interests are cancer genetics and clinical research through the Urologic Oncology Program and the Cancer Genetics Program. The Kim Lab is focused on understanding genetic and epigenetic events involved in the initiation and progression of renal cell carcinoma (RCC) and bladder cancer. Through NextGeneration sequencing of primary human tumors and the use of genetically engineered mouse models (GEMMs), as well as in vitro systems, the Kim Lab goal is to identify the critical genomic and epigenetic changes that are drivers of RCC and bladder cancer.|
|Jen-Jen Yeh, MD||Professor, Vice Chair of Research, Department of Surgery; UNC-LCCC||Dr. Yeh’s research interests focus on the role of tumor and stroma molecular subtypes in pancreatic cancer, the study of novel therapeutic targets, the identification of novel therapies, and pancreatic and colorectal cancer. Dr. Yeh also leads the research component of the Complex Surgical Oncology Fellowship Program and as the Associate Program Director led the previously funded Surgical Oncology T32.|
Affiliated Preceptors serve as co-advisors with a UNC-GO primary preceptor, and as consultants in one or more areas of expertise. Both primary and affiliated preceptors provide mentorship on education, research, or career opportunities.
Fourteen affiliate preceptors with appointments in the UNC School of Medicine and/or UNC-LCCC are committed to providing additional expertise to UNC-GO trainees to enhance overall academic and research experiences. Many of the affiliated preceptors are talented junior scientists who bring expertise in specific areas and cutting-edge methods that enhance the rigor and sustainability of the program’s training, or clinically-oriented faculty who provide insights on issues of health system quality. Additional affiliate preceptors may be added to the UNC-GO list of mentors as UNC-GO trainees identify additional faculty within Hematology/Oncology and Surgical, Gynecologic, Urologic, and Radiation Oncology with whom they wish to conduct their research.
|Affiliate Preceptors||Department(s)||Area of interest|
|Anne W. Beaven, MD||Assoc. Prof., Hematology/Oncology;
|Dr. Beaven is Director of the Lymphoma Program. Her research is focused on patients with all types of Hodgkin and non-Hodgkin lymphoma. She is particularly interested in the management of systemic T cell non-Hodgkin lymphoma (PTCL) and cutaneous lymphomas. She is developing trials to determine the best treatments for the very old (>80 years) patients.|
|Laura C. Hanson, MD MPH||Prof. in Geriatric Medicine;
|Dr. Hanson is Director of the Palliative Care Program. She leads a program of research at the interface of geriatrics and palliative care, to measure and improve quality of health care for older patients made vulnerable by serious illness, with a primary disease focus on cancer and on advanced dementia.|
|Trevor A. Jolly, MBBS||Asst. Prof. Divisions of Geriatric Medicine and Hematology/Oncology;
|Dr. Jolly’s research is focused on establishing the feasibility of geriatric assessment in both in-patient and outpatient multidisciplinary tertiary referral cancer center clinics and community Oncology practices.|
|Jennifer L. Lund, PhD||Asst. Prof., Epidemiology, School of Public Health;
|Dr. Lund’s research focuses at the intersection of aging, multi-morbidity and Oncology through health services and comparative effectiveness research. Her research aims to generate robust evidence regarding the uses, benefits and harms of medical interventions for older cancer patients with a special interest in polypharmacy.|
|Deborah K. Mayer, PhD RN AOCN FAAN||Professor of Nursing; UNC-LCCC||Dr. Mayer is Director of UNC-LCCC Cancer Survivorship. She is an advanced practice Oncology nurse and has 40 years of experience in cancer nursing practice, education, research and management. Her program of research focuses on the issues facing cancer survivors and improving cancer care. Dr. Mayer is also a member of the National Cancer Institute’s Cancer Moonshot Blue Ribbon Panel. She offers a clinical rotation in cancer survivorship for oncology fellows.|
|Matthew E. Nielsen, MD MS||Assoc. Prof. of Urology; UNC-LCCC||Dr. Nielsen is Director of Urologic Oncology. He serves as Adjunct Assistant Professor in the Departments of Epidemiology and Health Policy & Management at the UNC Gillings School of Global Public Health. Dr. Nielsen’s research in medical decision making, cancer care quality and treatment outcomes.|
|Kirsten A. Nyrop, PhD||Res. Asst. Prof., Hematology/Oncology||Dr. Nyrop is Deputy Director for Research, Lineberger geriatric Oncology Program. She is a health services researcher whose research interest is intervention and dissemination studies focused on preserving function and quality of life in older cancer patients during and after treatment.|
|Timothy Platts-Mills, MD MSc||Asst. Prof in Emergency Medicine; joint appointments in Anesthesiology, Medicine, Geriatrics||Dr. Platts-Mills’ research examines the determinants of persistent pain and functional decline after motor vehicle collision among older adults. A related area of research interest is improving patient education, and physician decision making regarding pharmacologic agents for the outpatient treatment of acute musculoskeletal pain in older adults. His research group is also developing a protocol to screen for elder abuse in the Emergency Department.|
|Katherine Reeder-Hayes, MD MBA MSc||Asst. Prof., Hematology/Oncology, UNC-LCCC||Dr. Reeder-Hayes is a clinically trained medical oncologist specializing in breast cancer with a research focus in comparative effectiveness of cancer treatments and cancer treatment disparities. Her research interests include the contribution of treatment variations and organizational characteristics to race and age disparities in cancer outcomes, effectiveness of breast cancer treatment paradigms in elderly women, and adherence to endocrine therapy in breast cancer survivors. Her experience includes analysis of large secondary databases, cost-effectiveness analysis, survey development and qualitative methods.|
|Ellen Roberts, PhD MPH||Res. Assoc. Prof.,
|Dr. Roberts is Academic Coordinator of Geriatric Medical Education for the UNC School of Medicine and for the UNC Center for Aging and Health, where her role includes mentoring the Geriatric Fellows and UNC medical students. She is also Program evaluator for the T35 Summer Medical Student Training in Aging Research (MSTAR). She has mentored over one hundred medical students, fellows and faculty members as well as serving on doctoral dissertation committees.|
|Hanna Sanoff, MD MPH||Assoc. Prof. Hematology/Oncology;
|Dr. Sanoff is Section Chief, GI Medical Oncology. Her research is focused on refining treatment selection for patients with gastrointestinal cancers. She is particularly interested in how to optimize treatment for understudied and high risk populations of patients, and does so through a combination of clinical trials of new drugs and new drug combinations, trials designed to discover biomarkers of treatment-related toxicity, and through comparative effectiveness research that investigates the real-world effectiveness of our cancer treatments.|
|Angela B. Smith, MD MS||Asst. Prof.,
|Dr. Smith has a background in health services research and biostatistics with particular interests in patient-centered outcomes research, risk stratification, and quality of care for invasive bladder cancer. She has a major interest in patient reported symptoms and integrating patients and caregivers into the research process.|
|Hung-Jiu “Ray” Tan, MD||Asst. Prof.
|Dr. Tan’s specialty is Urologic Oncology and his research focuses on frailty, aging and cancer care delivery as well as the comparative effectiveness of new cancer treatments.|
|Sasha Tuchman, MD MHS||Assoc. Prof. Hematology/Oncology; UNC-LCCC||Dr. Tuchman is Director of the UNC Multiple Myeloma and Amyloidosis Program. He studies all forms of plasma cell disorders with specific interests in amyloidosis and multiple myeloma in senior patients.|
|Jared Weiss, MD||Assoc. Prof. Hematology/Oncology; UNC-LCCC||Dr. Weiss’ is Section Chief, Thoracic and Head/Neck Cancer. His research is focused on clinical trials in lung cancer and head/ neck cancer. He has a major interest in chemotherapy for lung cancer in older patients. He is also interested in body composition, age, and treatment outcomes in older patients with aero-digestive tract tumors.|
|William A Wood, MD||Assoc. Prof. Hematology/Oncology; UNC-LCCC||Dr. Wood’s research interests involve outcomes and health services research in stem cell transplantation and hematologic malignancies. Current research includes examining physiological fitness, biomarkers of aging, and the early post-transplant patient-reported “symptom profile” to construct risk models of morbidity and mortality following transplant. He has a major interest in “wearable” activity trackers as a predictor of treatment outcomes.|